Trial Profile
Relative Bioavailability of Single Oral Dose of BI 113608 When Administered Alone or in Combination With Multiple Oral Doses of Ketoconazole or Voriconazole in Healthy Male Subjects (an Open-label, Randomised, Three-period Cross-over Trial)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Mar 2017
Price :
$35
*
At a glance
- Drugs BI 113608 (Primary) ; Ketoconazole; Voriconazole
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Mar 2013 Planned End Date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov record.
- 06 Mar 2013 Planned End Date changed from 1 Apr 2013 to 1 Mar 2013 according to the ClinicalTrials.gov record.